The question of whether Lactobacillus rhamnosus GG (LGG) can reduce Enterobacteriaceae levels in the gut is an area of active research, and the evidence is suggestive but not conclusive across all populations.

• Some studies, particularly in preterm infants and children with acute gastroenteritis, have shown that LGG supplementation can help reduce the relative abundance of potentially pathogenic Enterobacteriaceae while promoting beneficial bacteria like bifidobacteria and lactobacilli.
• The proposed mechanism involves LGG producing lactic acid and antimicrobial compounds (e.g., bacteriocins), lowering intestinal pH, and competing for adhesion sites and nutrients, which can inhibit the growth of Enterobacteriaceae.
• However, results vary depending on the baseline gut microbiota, dosage, duration of supplementation, and health status of the individual. In some adult populations with a stable microbiota, the effect may be more modest.

In summary: LGG shows promise for reducing Enterobacteriaceae in certain clinical contexts (especially in early life or dysbiosis), but the evidence is not uniformly strong across all populations. Further targeted research would help clarify its effectiveness for this specific outcome.